ImmunoCellular
Therapeutics, Ltd. introduced that the company has finished joining for its
Phase II randomized, double-blinded, placebo-controlled, multi-center trial of
the dendritic cell-based cancer vaccination ICT-107 for remedy for
glioblastoma. An entire of 278 affected individuals at 25 collaborating sites
appear to have been enrolled within this trial, which was started in January
2011.
"We perceive that ICT-107 can
be seen as next generation of cancer immunotherapy by focusing on both tumor
cells and cancer stem cells utilizing a dendritic cell-based vaccination," said John. S. Yu, MD, ImmunoCellular's Interim
Chief Executive Officer.
"We
sincerely appreciate the oncology communal interest in the ICT-107 clinical
program as well as their shared interest in discovering the therapeutic
potential of this potentially discovery technique, as reflected within the pace
of enrollment within the trial. I congratulate the ImmunoCellular clinical team
for that effective milestone in proficiently and rapidly finishing joining in
this difficult clinical trial."
No comments:
Post a Comment